1. Home
  2. PRSO vs APRE Comparison

PRSO vs APRE Comparison

Compare PRSO & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peraso Inc.

PRSO

Peraso Inc.

HOLD

Current Price

$0.96

Market Cap

7.8M

Sector

Technology

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.68

Market Cap

8.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRSO
APRE
Founded
2008
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
8.4M
IPO Year
2000
2019

Fundamental Metrics

Financial Performance
Metric
PRSO
APRE
Price
$0.96
$0.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$3.00
$5.50
AVG Volume (30 Days)
13.4M
76.8K
Earning Date
03-16-2026
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
86.27
21.22
EPS
N/A
N/A
Revenue
$14,573,000.00
N/A
Revenue This Year
$24.41
N/A
Revenue Next Year
$32.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.99
N/A
52 Week Low
$0.52
$0.55
52 Week High
$2.37
$2.30

Technical Indicators

Market Signals
Indicator
PRSO
APRE
Relative Strength Index (RSI) 43.83 41.99
Support Level $0.85 $0.55
Resistance Level $1.04 $0.95
Average True Range (ATR) 0.15 0.06
MACD -0.06 -0.01
Stochastic Oscillator 2.57 17.41

Price Performance

Historical Comparison
PRSO
APRE

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Share on Social Networks: